NCT01500863

Endometrial Receptivity After GnRH Agonist Triggering

Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: IVI Madrid · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

Conventional luteal phase support after human chorionic gonadotrophin (hCG) triggering in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) provides adequate pregnancy rates and live birth rates, but Ovarian hyperstimulation syndrome (OHSS) still occurs in 1-3% of the patients. If gonadotropin-releasing hormone agonist (GnRHa) are used instead of hCG, OHSS does not occur, but clinical results are somehow diminished. By testing different luteal support protocols on women undergoing GnRHa triggering, the investigators aim to find out which protocol resembles the most the gene expression profile observed after hCG triggering and conventional luteal phase support, in order to choose it as the most adequate in terms of endometrium receptivity and safety (OHSS incidence).

Conditions

• Ovarian Hyperstimulation Syndrome

Interventions

Type	Name	Description
DRUG	hCG	single shot of 6500 IU hCG s.c. at the time of triggering
DRUG	triptorelin	single shot of 0.2mg triptorelin s.c. at the time of triggering
DRUG	Triptorelin, estradiol valerate, micronized vaginal progesterone	4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
DRUG	triptorelin, hCG	single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
DRUG	triptorelin, hCG	Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
DRUG	triptorelin, recombinant LH	300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-05-01
• First posted: 2011-12-29
• Last updated: 2016-10-26

Locations

1 site across 1 country: Spain